Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1

Nonagase Yoshikane; Yonesaka Kimio; Kawakami Hisato; Watanabe Satomi; Haratani Koji; Takahama Takayuki; Takegawa Naoki; Ueda Hiroto; Tanizaki Junko; Hayashi Hidetoshi; Yoshida Takeshi; Takeda Masayuki; Chiba Yasutaka; Tamura Takao; Nakagawa Kazuhiko; Tsurutani Junji

doi:10.18632/oncotarget.12743

免费注册

赞收藏引用

科研之友

微信

新浪微博

Facebook

分享链接

Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1

作者：Nonagase Yoshikane; Yonesaka Kimio; Kawakami Hisato; Watanabe Satomi; Haratani Koji; Takahama Takayuki; Takegawa Naoki; Ueda Hiroto; Tanizaki Junko; Hayashi Hidetoshi; Yoshida Takeshi; Takeda Masayuki; Chiba Yasutaka; Tamura Takao; Nakagawa Kazuhiko; Tsurutani Junji

来源：Oncotarget, 2016, 7(51): 84860-84871.

DOI：10.18632/oncotarget.12743